Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Peptide mimetics of immunoglobulin A (IgA) and FcαRI block IgA-induced human neutrophil activation and migration.

Heineke MH, van der Steen LPE, Korthouwer RM, Hage JJ, Langedijk JPM, Benschop JJ, Bakema JE, Slootstra JW, van Egmond M.

Eur J Immunol. 2017 Oct;47(10):1835-1845. doi: 10.1002/eji.201646782. Epub 2017 Sep 6.

2.

Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.

van Egmond M, Vidarsson G, Bakema JE.

Immunol Rev. 2015 Nov;268(1):311-27. doi: 10.1111/imr.12333. Review.

PMID:
26497530
3.

Antibody-opsonized bacteria evoke an inflammatory dendritic cell phenotype and polyfunctional Th cells by cross-talk between TLRs and FcRs.

Bakema JE, Tuk CW, van Vliet SJ, Bruijns SC, Vos JB, Letsiou S, Dijkstra CD, van Kooyk Y, Brenkman AB, van Egmond M.

J Immunol. 2015 Feb 15;194(4):1856-66. doi: 10.4049/jimmunol.1303126. Epub 2015 Jan 12.

4.

Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.

Bakema JE, van Egmond M.

Curr Top Microbiol Immunol. 2014;382:373-92. doi: 10.1007/978-3-319-07911-0_17. Review.

PMID:
25116109
5.

IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I.

Aleyd E, van Hout MW, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, van Egmond M.

J Immunol. 2014 Mar 1;192(5):2374-83. doi: 10.4049/jimmunol.1300261. Epub 2014 Feb 3.

6.

Neutrophils as effector cells for antibody-based immunotherapy of cancer.

van Egmond M, Bakema JE.

Semin Cancer Biol. 2013 Jun;23(3):190-9. doi: 10.1016/j.semcancer.2012.12.002. Epub 2012 Dec 31. Review.

PMID:
23287459
7.

Blocking Fcα receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies.

van der Steen LP, Bakema JE, Sesarman A, Florea F, Tuk CW, Kirtschig G, Hage JJ, Sitaru C, van Egmond M.

J Immunol. 2012 Aug 15;189(4):1594-601. doi: 10.4049/jimmunol.1101763. Epub 2012 Jul 16.

8.

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.

Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JG, van Egmond M.

Eur J Immunol. 2012 Jul;42(7):1815-21. doi: 10.1002/eji.201141982.

9.

The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.

Bakema JE, van Egmond M.

Mucosal Immunol. 2011 Nov;4(6):612-24. doi: 10.1038/mi.2011.36. Epub 2011 Sep 21. Review.

PMID:
21937986
10.

Immunoglobulin A: A next generation of therapeutic antibodies?

Bakema JE, van Egmond M.

MAbs. 2011 Jul-Aug;3(4):352-61. Epub 2011 Jul 1. Review.

11.

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.

Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, Lohse S, Glennie MJ, Medema JP, van Egmond M.

J Immunol. 2011 Jul 15;187(2):726-32. doi: 10.4049/jimmunol.1002581. Epub 2011 Jun 8.

12.

c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain.

Bakema JE, Hiemstra IH, Bakker J, de Haij S, Kok Y, Adema G, van Egmond M, Coffer PJ, van de Winkel JG, Leusen JH.

Eur J Immunol. 2010 Jul;40(7):2035-40. doi: 10.1002/eji.200939985.

13.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH.

Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.

14.

Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4.

van der Steen L, Tuk CW, Bakema JE, Kooij G, Reijerkerk A, Vidarsson G, Bouma G, Kraal G, de Vries HE, Beelen RH, van Egmond M.

Gastroenterology. 2009 Dec;137(6):2018-29.e1-3. doi: 10.1053/j.gastro.2009.06.047. Epub 2009 Jun 23.

PMID:
19555692
15.

Inside-out regulation of Fc alpha RI (CD89) depends on PP2A.

Bakema JE, Bakker A, de Haij S, Honing H, Bracke M, Koenderman L, Vidarsson G, van de Winkel JG, Leusen JH.

J Immunol. 2008 Sep 15;181(6):4080-8.

16.

Protein 4.1G binds to a unique motif within the Fc gamma RI cytoplasmic tail.

Beekman JM, Bakema JE, van der Poel CE, van der Linden JA, van de Winkel JG, Leusen JH.

Mol Immunol. 2008 Apr;45(7):2069-75. Epub 2007 Nov 26.

PMID:
18023480
17.

Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction.

Bakema JE, de Haij S, den Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, van de Winkel JG, Leusen JH.

J Immunol. 2006 Mar 15;176(6):3603-10.

18.

Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity.

Beekman JM, Bakema JE, van de Winkel JG, Leusen JH.

Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10392-7. Epub 2004 Jun 30.

19.

Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin.

Beekman JM, Bakema JE, van der Linden J, Tops B, Hinten M, van Vugt M, van de Winkel JG, Leusen JH.

J Biol Chem. 2004 Aug 6;279(32):33875-81. Epub 2004 May 25.

20.

A generic sequencing based typing approach for the identification of HLA-A diversity.

Scheltinga SA, Johnston-Dow LA, White CB, van der Zwan AW, Bakema JE, Rozemuller EH, van den Tweel JG, Kronick MN, Tilanus MG.

Hum Immunol. 1997 Oct;57(2):120-8.

PMID:
9438203

Supplemental Content

Loading ...
Support Center